Introduction
Interferons (IFNs) are a family of multifunctional secreted proteins characterized by their abilities to interfere with virus infection and replication (1, 2) . IFNs can indirectly inhibit viral production by reducing the growth of target cells and by stimulating their susceptibility to apoptotic processes (3, 4) or by promoting the recognition and the cytotoxic killing of infected cells by the immune system (5, 6) . IFNs also act directly at various steps of the viral multiplication cycle through the products of specific but usually overlapping sets of cellular genes induced in the target cells and involved in RNA and protein metabolism and signaling as well (7, 8) . Until now, three IFN-regulated pathways have been considered to be involved in these processes: the double-stranded RNAdependent protein kinase R (PKR) (9) (10) (11) , the 2-5A/RNase L system (12, 13) and the Mx proteins (14) (15) (16) . PKR is a serine/threonine kinase which, after binding to dsRNA, phosphorylates the protein synthesis initiation factor eIF2 and the inhibitor of NFκB (I-κB) resulting in the inhibition of protein synthesis and specific transcription regulation [reviewed in (17) (18) (19) ]. RNase L is a dormant cytosolic endoribonuclease that is activated by short oligoadenylates produced by the 2'-5' oligoadenylate synthetase (2-5OAS) following viral infection or IFN exposure [reviewed in (2, 13) ].
(VSV) suggesting that another presently unknown, mechanism contribute to the IFN-dependent antiviral response (20) .
We have isolated a human cDNA encoding an IFN-induced protein, which we have termed ISG20 for IFN Stimulated Gene product of 20 kDa (21, 22) . ISG20 is a member of the 3' to 5' exonuclease superfamily that includes RNases (such as RNase T and D), the proofreading domains of the Pol I family of DNA polymerases, and DNases that exist as independent proteins (23) .
Homology within the superfamily is concentrated at three conserved exonuclease motifs termed ExoI, ExoII, and ExoIII (23) . Based on these observations we have demonstrated that ISG20 is a 3' to 5' exonuclease in vitro with specificity for single-stranded RNA and to a lesser extent for DNA, suggesting that ISG20 could be involved in the antiviral function of IFN against RNA viruses (24) .
Notably, ISG20 is the second known RNase regulated by IFN, along with RNase L (24) .
In this report, we have analyzed the ability of ISG20 to protect cells against various viral infections. We demonstrate that in the absence of IFN treatment, ISG20 overexpressing-cells showed resistance to infections by VSV, influenza virus, and EMCV but not to adenovirus. A single amino acid substitution in the conserved exonuclease motif ExoII completely abolished both the exonuclease and the antiviral activities of ISG20, demonstrating that the protective effects were due to ISG20 exonuclease activity. We showed that the antiviral action of IFN, against VSV, was reduced in cells expressing the inactive ExoII-mutant of ISG20 protein, suggesting that the antiviral activity of IFN, against its virus, is partly mediated by ISG20. As ISG20 is a new RNase induced by IFN, these data support the idea that it might represent a novel antiviral pathway in the mechanism of IFN action.
by guest on http://www.jbc.org/ Downloaded from thawed three times. The supernatants were serially diluted, and the virus titers were measured alternatively by a plaque assay on L929 cells as previously described (25) or by an end-point method (26) . Transient transfection experiments were performed in 6-well plates by the Lipofectamine Plus Reagent method (Invitrogen, France). Twenty-four hours after transfection, cells were washed twice in phosphate-buffer-saline (PBS) and infected with VSV at an MOI of 0.1 in DMEM medium supplemented with 10% FBS. Infection with adenovirus was performed in 6-well plates at 10 MOI in RPMI medium supplemented with 2% FBS. After 2 h, the cells were washed in PBS, placed in RPMI medium supplemented with 10% FBS and then cultured for 24 h at 37°C before the β-galactosidase assay using the β-Galactosidase Enzyme Assay System (Promega, France).
Antibodies-Specific ISG20 antibody was developed from the ISG20-GST-fusion protein produced in the BL21-DE3 E. Coli strain and purified by affinity chromatography on glutathione Sepharose. This material was injected into mice to raise a polyclonal antiserum. The polyclonal ISG20 antibody was used in Western blot analysis to detect endogenous ISG20 protein. Rabbit polyclonal anti-VSV antibodies were previously described (27) . Monoclonal antibody against α−tubulin (clone B-5-1-2) was purchased from Sigma Aldrich.
Immunofluorescence analysis-Confocal immunofluorescence was performed with rabbit polyclonal anti-VSV antibody (27) . The cells were fixed 5 min in PBS containing 3.7% formaldehyde. VSV antigens were detected with a rabbit anti-VSV antibody (1:500 dilution) and revealed with a fluorescein-conjugated (FITC-conjugated) secondary antibody (Beckman Coulter, Marseille, France). Slides were viewed using a Leika microscopic and image files were processed with the Adobe Photoshop program.
Western blotting analysis-Cells (1 x 10 6 ) were resuspended in 50 µl of loading buffer (10 mM Tris-HCl pH 6.8, 1% SDS, 5 mM EDTA, and 50% glycerol) and incubated 5 min at 95°C. The proteins were fractionated on 10% SDS-PAGE and transferred onto a nitrocellulose membrane.
After a blocking step, the membrane was hybridized with the appropriate antibodies and then revealed by using a chemiluminescent detection system (ECL, Amersham Pharmacia Biotech). 
Results

ISG20 confers resistance to VSV infection in transiently transfected HeLa cells-We have
previously shown that ISG20 is a 3' to 5' exonuclease that specifically degrades in vitro singlestranded RNA substrates (and to a lesser extent single-stranded DNA substrates) (24) . Homology within the superfamily is concentrated at three conserved exonuclease motifs termed ExoI, ExoII, and ExoIII (23) . In accordance with this information, a site-specific aspartate to glycine residue mutation in the Exo II conserved motif of ISG20 (mut-ISG20D94G, Fig.1A ) abolished its activity (24) . Because IFN causes a strong induction of ISG20 expression (21, 29) , these data suggested that the protein could be an active player in the antiviral action mediated by IFNs against RNA viruses.
The potential antiviral activity of ISG20 against the vesicular stomatitis virus (VSV), a negative- The selected clones were then infected with 0.1 MOI of VSV. A stable population of HeLa cells transfected with the empty pCiNeo vector (HeLa-pCiNeo) was used to determine viral infection efficiencies. Twenty-four hours later, the viral productions were determined as previously described.
The mean value of three independent experiments presented in Fig. 2B , show a reproducible protective effect ranging from two to three log reduction of viral production in the wt-ISG20 HeLa cells, as compared with the HeLa-pCiNeo cells. A low ISG20 protein expression was sufficient to promote an efficient protection against VSV. To determine whether the viral resistance observed was dependent on the amount of viral particles used for infections, an additional experiment was performed with 1 MOI of VSV. As expected, the amplitude of ISG20 viral protection was decreased when the cells were infected at high MOI (Fig. 2C) . Clearly, these data strengthen our findings in
transient transfection experiments and demonstrate the role of ISG20 in the antiviral actions of IFNs against VSV. As VSV particle production was significantly higher in mut-ISG20 HeLa cells, these data confirmed the dominant-negative activity of the Exo II inactive-mutant of ISG20 protein. (Fig. 3A) . The effect of wt-ISG20 was also confirmed by Western blot analysis using a rabbit polyclonal antibody able to detect the major structural proteins of VSV, the nucleoproteins N and NS (40 kDa), the matrix protein M (25 kDa), and the glycoprotein G (69 kDa) (27) . In accordance with the inhibition of VSV mRNA expression, a strong reduction in VSV antigen expression was observed in the wt-ISG20 clone as compared with mut-ISG20 and HeLa-pCiNeo cells (Fig. 3B) .
ISG20 inhibits VSV RNA and protein accumulation-
The VSV antigens remained undetectable in pCiNeo HeLa cells treated with 500 u/ml of Huα2aIFN used as positive control.
ISG20 partly mediates the IFN antiviral activity against VSV-We have previously shown
that ≥90% of ISG20 RNase activity was inhibited when RNase assays were performed, in vitro, in the presence of the inactive Exo II-mutated ISG20 protein (24) . The fact that the amounts of VSV produced by transiently or stably transfected HeLa cells with the mut-ISG20 construct were significantly higher than that produced by cells transfected with the empty pCiNeo vector strongly suggest that mut-ISG20 could exhibit dominant-negative effects in vivo (24) . We took advantage of this inhibitory effect to test the contribution of ISG20 to the IFN-mediated antiviral activity. To this aim, the antiviral action of IFN, on mut-ISG20 HeLa cells, was compared with that observed on HeLa/pCiNeo cells. The cells were treated for 16 h with 500 u/ml of Hu-α2aIFN and then infected with 0.1 MOI of VSV. Twenty-four hours later, the virus titers were determined as described in Experimental Procedure. The results presented in Fig. 4 , show that overexpression of mut-ISG20
protein reduced the ability of IFN to interfere with VSV infection. These data confirm that the antiviral activity of IFN against VSV infection is partly mediated by ISG20.
Overexpression of ISG20 confers resistance to influenza virus and EMCV infections but
not to adenovirus infection-Because the different IFN-induced antiviral pathways described so far present some virus specificities, we then analyzed the potential ISG20 antiviral activity against two other RNA genomic viruses, the influenza virus (an orthomyxovirus) and EMCV (a picornavirus).
The wt-ISG20, mut-ISG20, and HeLa/pCiNeo cells were infected with these viruses at 0.1 MOI.
The viral productions were determined as described for VSV. As shown in Fig. 5A , a strong reduction in influenza virus production was observed with the wt-ISG20 clone but not with the mut-ISG20. However, this decrease in viral multiplication was lower than the one observed with VSV.
On the other hand, only a weak protective effect was observed for EMCV (Fig.5B) . These data show that ISG20 presents antiviral specificities among the viruses tested and suggest that this protein acts preferentially against VSV in the IFN-mediated antiviral barrier. Interestingly, the expression of mut-ISG20 did not affect the action of IFN against influenza virus and EMCV (data not shown), suggesting that the contribution of ISG20 against these viruses is probably minor in comparison with the other IFN-induced pathways.
We also addressed the question of the ability of ISG20 to interfere with the replication of a DNA genomic virus. To this aim, the HeLa/pCiNeo cells and the wt-ISG20 and mut-ISG20 clones were infected with a derivative adenovirus strain bearing a β-galactosidase reporter gene at an MOI of 10. Twenty-four hours after infection, β-galactosidase-expressing cells were detected by histochemical staining and light microscopy analysis. In addition, cellular extracts were prepared and the β-galactosidase activity determined as described in Experimental Procedures. As a control, the cells were infected for 12 h with 1 MOI of VSV, and VSV antigen expression was monitored by immunofluorescence. According to our previous data, a strong inhibition of VSV antigen expression was observed in wt-ISG20 clone (Fig. 5C ). On the contrary, no inhibition of adenovirus protein expression was observed in wt-ISG20 HeLa cells, strengthening the idea of virus specificity for ISG20 activity. that we have termed ISG20 (21, 22, 29) . We provided biochemical evidences that ISG20 is a processive 3' to 5' exonuclease specific for single-stranded RNA (24) . In the present report, we analyzed the potential antiviral activity of ISG20.
Expression of ISG20 in cells triply deficient in PKR,
We demonstrated that stable and constitutive expression of ISG20 confers resistance to VSV, influenza virus, and EMCV infection in HeLa cells, providing an alternative antiviral pathway against RNA genomic viruses. The same experiments were performed in transiently transfected cells, demonstrating that the protective effect was due to ISG20 expression and was not a characteristic of the selected clones. However, the protective efficiency of ISG20 seems to be variable even among RNA viruses since protection against influenza virus and EMCV was less efficient than against VSV infection. In accordance with that, an inactive mutant ISG20 protein able to inhibit the ISG20 exonuclease activity, in vitro, significantly reduced the ability of IFN to block VSV but not EMCV or influenza virus developments. These data strongly suggest that ISG20 partly mediates the IFN antiviral effect against VSV with minor contribution against influenza virus and EMCV infections. was shown to be up-regulated during activation programs induced in human macrophages by some bacterial strains, providing a more general role of ISG20 against different kinds of pathogens (53, 54) . Further studies are needed to determine exactly the biological contribution of ISG20 in these processes.
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